Obesity or Overweight Clinical Trial
Official title:
Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-Weekly in Chinese Participants With Overweight or Obesity
This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1 year.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03629301 -
Obesity Treatment Using an Internet-delivered Intervention Based on the Diabetes Prevention Program in Mexican Adults
|
N/A | |
| Active, not recruiting |
NCT05607680 -
A Study of IBI362 in Participants With Obesity or Overweight
|
Phase 3 | |
| Completed |
NCT05153590 -
A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
|
||
| Recruiting |
NCT05813925 -
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
|
Phase 3 |